3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
76
Neoplasms
16
Prostatic Neoplasms, Castration-Resistant
14
Neoplasm Metastasis
9
Breast Neoplasms
9
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
5
Metastatic Castration-Resistant Prostate Cancer
5
Colorectal Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Metastatic Castration-resistant Prostate Cancer
3
Melanoma
3
Bulbo-Spinal Atrophy, X-Linked
3
mCRPC
2
Recurrence
2
Pancreatic Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castrate-Resistant Prostate Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Seizures
1
Interventions
pembrolizumab
2
radium Ra 223 dichloride
1
enzalutamide
1
efineptakin alfa
1
abiraterone
1
Radium-223
1
Pluvicto
1
PSMA-11
1
Lutetium-177
1
Lutetium
1
Injections
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
enzalutamide
×
Clear all
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled